$VRTX · VERTEX PHARMACEUTICALS INC / MA SEC Filings
Position Tracker tracks 12 SEC EDGAR filings for VERTEX PHARMACEUTICALS INC / MA ($VRTX) from July 23, 2026 through November 3, 2026, including 0 Form 10-K annual reports, 2 Form 10-Q quarterly earnings reports, 3 Form 8-K current event disclosures, and 6 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$VRTX 10-Q — VERTEX PHARMACEUTICALS INC / MA
A 40% operating-income drop at a $134B biotech giant despite double-digit revenue growth signals a costly transition period as the Crinetics deal and new launches pressure margins.
$VRTX 8-K — VERTEX PHARMACEUTICALS INC / MA
Vertex's earnings show a company in transition: legacy CF cash flows are funding an aggressive diversification push, but the Crinetics acquisition is materially compressing GAAP…
$VRTX 4 — Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated filed a Form 4 with the Securities and Exchange Commission reporting a change in beneficial ownership for Jasper van Grunsven, an officer of…
$VRTX 3 — Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated filed a Form 3 with the SEC on September 10, 2026, covering an initial statement of beneficial ownership for Jasper van Grunsven. The filing…
$VRTX 4 — Vertex Pharmaceuticals Incorporated
This Form 4 filing reports a change in beneficial ownership for Kristen Ambrose, Vertex Pharmaceuticals' Senior Vice President and Chief Accounting Officer. On August 28, 2026,…
$VRTX 8-K — Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated disclosed in a Form 8-K filed on September 1, 2026, that it appointed Jonathan Poole as Executive Vice President and Chief Financial Officer,…
$VRTX 4 — Vertex Pharmaceuticals Incorporated
This filing is a Form 4 statement of changes in beneficial ownership filed with the SEC for Bruce I. Sachs, a director of Vertex Pharmaceuticals Incorporated. It reports a singl…
$VRTX 144 — Vertex Pharmaceuticals Incorporated
A Form 144 notice filed with the Securities and Exchange Commission on August 27, 2026, reports a proposed sale of Vertex Pharmaceuticals Incorporated common stock. The notice c…
$VRTX 10-Q — Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated filed its Form 10-Q quarterly report for the period ended June 30, 2026. The filing presents unaudited condensed consolidated financial state…
$VRTX 8-K — Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals reported second quarter 2026 total revenue of $3.33 billion, a 12% increase compared to the second quarter of 2025. The company said growth was driven by…
$VRTX 4 — Vertex Pharmaceuticals Incorporated
This SEC Form 4 filing by Vertex Pharmaceuticals Incorporated reports a change in beneficial ownership for Ourania Tatsis, the company’s Executive Vice President and Chief Regul…
$VRTX 4 — Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals filed a Form 4 with the SEC on July 23, 2026, reporting a change in beneficial ownership for Amit Sachdev, the company’s EVP Chief Patient and External Af…